Therapy of hypoparathyroidism with intact parathyroid hormone

What Was Tested

Researchers studied Parathyroid Hormone (PTH 1-84) in this clinical trial publication.

Hypoparathyroidism, a disorder characterized by low parathyroid hormone (PTH), is generally treated with oral calcium and vitamin D supplementation.

The researchers investigated the effects of PTH(1-84) treatment in 30 hypoparathyroid subjects for 24 months.

Who Took Part

The study group was 30 subjects.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a open-label study.

Nothing was hidden in this open-label Parathyroid Hormone (PTH 1-84) study: the subjects and staff both knew the treatment.

A time span of 24 months appears in the methods.

What Was Measured

The subject headings attached to it are Bone Density, Calcium, Femur Neck, Hormone Replacement Therapy, Hypoparathyroidism, Lumbar Vertebrae and Parathyroid Hormone.

What This Means in Plain Language

The paper is an open-label study of Parathyroid Hormone (PTH 1-84) in 30 subjects over 24 months.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2010 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.